ReviewMycotoxin research2025
Enzymatic detoxification of major mycotoxins: current status, challenges, and future prospective.
Review in Mycotoxin research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycotoxins are ubiquitous in cereals and cereal products worldwide, presenting substantial health hazards to both humans and animals. Enzymatic degradation has recently gained prominence as a highly effective, selective, and environmentally friendly approach to neutralizing mycotoxins, converting them into non-toxic or less toxic compounds. Herein, we provide a comprehensive overview of the enzymatic properties and degradation pathways of mycotoxin-degrading enzymes that target major mycotoxins, including aflatoxins (AFs), ochratoxins (OTs), deoxynivalenol (DON), zearalenone (ZEN), and fumonisins (FUMs). The identification of multiple mycotoxin-degrading enzymes, such as peroxidases, laccases, esterases, and oxidoreductases, has paved the way for transforming mycotoxins into less or non-toxic products through diverse pathways, offering a promising avenue for complete detoxification.
Indexed as
Identifiers
40991165What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.